Streetbeat News

Equity Actions

KTTA

Pasithea Therapeutics Corp. (NASDAQ:KTTA) has selected a lead therapeutic candidate for its PAS-003 program, a humanized monoclonal antibody that targets α5β1 integrin, a protein found to be overexpressed in both human and mouse subjects with amyotrophic lateral sclerosis (ALS). The company has performed extensive mAb screening and characterization to enable selection of a lead therapeutic candidate with optimal properties for the treatment of ALS. The humanized lead candidate is a potent inhibitor of the primary ligand fibronectin (FN), has been optimized for high affinity and has high (sub-nanomolar) specificity with contact sites directly adjacent to the FN binding site documented by cryogenic electron microscopy (cryo-EM).

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:11 pm

NVAX

Novavax has announced plans to initiate an additional cost reduction program, aiming to reduce its 2024 expenses by over $300 million.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:08 pm

TGNA

TEGNA Inc. has entered into a $325 million accelerated share repurchase agreement. This move is expected to quickly reduce the number of shares outstanding, potentially increasing the value of remaining shares.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:07 pm

XRAY

DENTSPLY SIRONA's board of directors has authorized an additional $1B share repurchase program.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:06 pm

BSGM

BioSig Technologies, Inc. (BSGM) has announced a registered direct offering priced at-the-market under Nasdaq rules. The offering is worth $2.5 million.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:02 pm

COLL

Collegium Pharmaceutical, Inc. has announced a $25 million accelerated share repurchase (ASR) program. The ASR is expected to be funded from the company's existing cash on hand.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:00 pm

ARCC

Ares Capital Corporation (ARCC) has announced the appointment of Scott Lem as its new Chief Financial Officer, effective from February 15, 2024. He will be succeeding Penni Roll.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:49 pm

BTTX

Better Therapeutics (NASDAQ:BTTX) reported Q3 losses of $(0.15) per share, beating the analyst consensus estimate of $(0.21) by 28.57%. This is a 68.75% increase over losses of $(0.48) per share from the same period last year. The company also raised $2.9M in October 2023 and has cash and cash equivalents of $6.6M. Lower operating expenses from restructuring will extend its runway into Q1 of 2024.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:42 pm

AAPL

GOOGL

MSFT

Morgan Stanley analysts suggest that Apple Inc. is best positioned to profit from the mainstream adoption of artificial intelligence (AI), ahead of competitors such as Google and Microsoft. The analysts argue that Apple's combination of hardware, software, and services, along with its commitment to user privacy, puts it in a prime position to take advantage of the AI field.

Portfolio Pulse from Sudhanshu Singh

November 09, 2023 | 12:37 pm

HCA

HCA Healthcare has provided a business outlook ahead of its Investor Day, targeting an adjusted EBITDA growth of 4-6% and diluted EPS growth of 8-12% over the next five years.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:34 pm